EMBRAMINE TEOCLATE

Investigational

Details

Stereochemistry	RACEMIC
Molecular Formula	C18H22BrNO.C7H7ClN4O2
Molecular Weight	562.886
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

CN1C2=C(N=C(Cl)N2)C(=O)N(C)C1=O.CN(C)CCOC(C)(C3=CC=CC=C3)C4=CC=C(Br)C=C4

InChI

InChIKey=UZJKOLCOUILXEJ-UHFFFAOYSA-N

InChI=1S/C18H22BrNO.C7H7ClN4O2/c1-18(21-14-13-20(2)3,15-7-5-4-6-8-15)16-9-11-17(19)12-10-16;1-11-4-3(9-6(8)10-4)5(13)12(2)7(11)14/h4-12H,13-14H2,1-3H3;1-2H3,(H,9,10)

HIDE SMILES / InChI

Molecular Formula	C7H7ClN4O2
Molecular Weight	214.609
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C18H22BrNO
Molecular Weight	348.277
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description

Embramine or mebrophenhydramine is an antiallergic agent. Embramine is a histamine H₁-receptor antagonist exerting anticholinergic activity. It may inhibit stimulated platelet functions by inhibiting phospholipase A2. It is prescribed for severe allergic conditions.

Approval Year

Targets

Targets

Primary Target	Pharmacology	Condition	Potency
Histamine H1 receptor 315	Antagonist 2,778

PubMed

Show entries

Title	Date	PubMed
Pharmacological intervention with platelet phospholipase A2.	2001	11802290
Cationic amphiphilic drugs and platelet phospholipase A(2) (cPLA(2)).	2002 Feb 15	12031829